← Leaderboards
James M Wilson
University Of Pennsylvania
$22,532,723
Attributed
$24,096,281
Total exposure
32
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.5M · FY2005–19$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$87,541,787 · 35
By mechanism
P01$57,362,532 · 18
P30$21,677,229 · 9
RC3$2,822,695 · 1
N01$2,050,706 · 1
R01$1,744,036 · 1
RC1$991,039 · 1
Top collaborators
- Mark L Batshaw5 shared
- Karen Kozarsky2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Daniel James Rader$77,348,993
- Kara A Bernstein$8,200,317
- Hiroki Morizono$1,332,034
- Marina Cuchel$7,792,390
- Ernest J Petersson$2,393,734
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorClinical TrialsProgramsSafetyGrantGene TransferAnimal ModelBaseImmunologyLiverAdeno-Associated Viral VectorCellsMouse ModelResearch PersonnelTransgenesAnimalsAdvisory CommitteesCellular MorphologyCapsidFundingPre-ClinicalDependovirusMolecular
Grant awards (141)
AAV Gene Therapy for Lipid Disorders$2,207,309
P01 · FY2019 · HL · contact PI
Project 3 - Next Generation AAV Vectors for Liver Gene Therapy$617,371
P01 · FY2019 · HL · contact PI
Administrative Core$124,649
P01 · FY2019 · HL · contact PI
AAV Gene Therapy for Lipid Disorders$2,139,766
P01 · FY2018 · HL · contact PI
Project 3 - Next Generation AAV Vectors for Liver Gene Therapy$513,696
P01 · FY2018 · HL · contact PI
Administrative Core$124,653
P01 · FY2018 · HL · contact PI
AAV Gene Therapy for Lipid Disorders$2,167,240
P01 · FY2017 · HL · contact PI
Molecular Therapy for Cystic Fibrosis$683,045
P30 · FY2017 · DK · contact PI
Project 3 - Next Generation AAV Vectors for Liver Gene Therapy$649,338
P01 · FY2017 · HL · contact PI
Administrative Core$129,648
P01 · FY2017 · HL · contact PI
Administrative Core$49,626
P30 · FY2017 · DK · contact PI
AAV Gene Therapy for Lipid Disorders$1,985,074
P01 · FY2016 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$1,057,475
P01 · FY2016 · HD · contact PI
Molecular Therapy for Cystic Fibrosis$688,858
P30 · FY2016 · DK · contact PI
Project 3 - Next Generation AAV Vectors for Liver Gene Therapy$504,110
P01 · FY2016 · HL · contact PI
Barriers to achieving stable gene therapy$257,835
P01 · FY2016 · HD · contact PI
Administrative Core$129,649
P01 · FY2016 · HL · contact PI
Administrative Core$76,235
P01 · FY2016 · HD · contact PI
Administrative Core$61,740
P30 · FY2016 · DK · contact PI
AAV Gene Therapy for Lipid Disorders$2,116,284
P01 · FY2015 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$1,058,067
P01 · FY2015 · HD · contact PI
Molecular Therapy for Cystic Fibrosis$694,501
P30 · FY2015 · DK · contact PI
Project 3 - Next Generation AAV Vectors for Liver Gene Therapy$533,309
P01 · FY2015 · HL · contact PI
Barriers to achieving stable gene therapy$255,904
P01 · FY2015 · HD · contact PI
Administrative Core$141,734
P01 · FY2015 · HL · contact PI
Administrative Core$74,337
P01 · FY2015 · HD · contact PI
Administrative Core$61,739
P30 · FY2015 · DK · contact PI
Gene Therapy for Urea Cycle Disorders$1,070,903
P01 · FY2014 · HD · contact PI
Molecular Therapy for CF and Genetic Diseases$807,759
P30 · FY2014 · DK · contact PI
Barriers to achieving stable gene therapy$256,006
P01 · FY2014 · HD · contact PI
Administrative Core$74,110
P01 · FY2014 · HD · contact PI
DNA virus as vectors for cardiovascular diseases$1,798,007
P01 · FY2013 · HL · contact PI
Molecular Therapy for CF and Genetic Diseases$1,093,528
P30 · FY2013 · DK · contact PI
Gene Therapy for Urea Cycle Disorders$1,068,145
P01 · FY2013 · HD · contact PI
T CELL RESPONSES IN LIVER GENE THERAPY$426,749
P01 · FY2013 · HL · contact PI
Administrative Core$250,179
P30 · FY2013 · DK · contact PI
Barriers to achieving stable gene therapy$201,812
P01 · FY2013 · HD · contact PI
Administrative Core$95,207
P01 · FY2013 · HD · contact PI
DNA virus as vectors for cardiovascular diseases$1,918,033
P01 · FY2012 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$1,196,049
P01 · FY2012 · HD · contact PI
Molecular Therapy for CF and Genetic Diseases$1,167,788
P30 · FY2012 · DK · contact PI
T CELL RESPONSES IN LIVER GENE THERAPY$436,582
P01 · FY2012 · HL · contact PI
Novel Adeno-Associated Viral Therapy for Wet Age-Related Macular Degeneration$304,421
R43 · FY2012 · EY
Administrative Core$268,527
P30 · FY2012 · DK · contact PI
Barriers to achieving stable gene therapy$262,109
P01 · FY2012 · HD · contact PI
Administrative Core$91,246
P01 · FY2012 · HD · contact PI
DNA virus as vectors for cardiovascular diseases$2,368
P01 · FY2012 · HL · contact PI
DNA virus as vectors for cardiovascular diseases$2,187,963
P01 · FY2011 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$1,198,336
P01 · FY2011 · HD · contact PI
Molecular Therapy for CF and Genetic Diseases$1,175,744
P30 · FY2011 · DK · contact PI
T CELL RESPONSES IN LIVER GENE THERAPY$434,055
P01 · FY2011 · HL · contact PI
Administrative Core$270,119
P30 · FY2011 · DK · contact PI
Immune Barriers to AAV Gene Therapy$171,192
P01 · FY2011 · HD · contact PI
Preclinical Studies of AAV Gene Therapy in MOuse Models of Urea Cycle Disorders$171,191
P01 · FY2011 · HD · contact PI
Administrative Core$171,191
P01 · FY2011 · HD · contact PI
Novel Adeno-Associated Viral Therapy for X-linked Retinitis Pigmentosa$2,822,695
RC3 · FY2010 · EY
DNA virus as vectors for cardiovascular diseases$2,269,387
P01 · FY2010 · HL · contact PI
Molecular therapy for CF and genetic diseases$1,178,972
P30 · FY2010 · DK · contact PI
NHLBI GTRP Preclinical Vector Production Core Laboratory$1,125,737
N01 · FY2010 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$998,305
P01 · FY2010 · HD · contact PI
Regulated Transgene Expression in the Retina$496,479
RC1 · FY2010 · EY · contact PI
T CELL RESPONSES IN LIVER GENE THERAPY$432,726
P01 · FY2010 · HL · contact PI
Administrative Core$273,347
P30 · FY2010 · DK · contact PI
Immune Barriers to AAV Gene Therapy$218,096
P01 · FY2010 · HD · contact PI
Gene Therapy for Urea Cycle Disorders$218,096
P01 · FY2010 · HD · contact PI
Preclinical Studies of AAV Gene Therapy in MOuse Models of Urea Cycle Disorders$142,615
P01 · FY2010 · HD · contact PI
Immune Barriers to AAV Gene Therapy$142,615
P01 · FY2010 · HD · contact PI
Administrative Core$142,612
P01 · FY2010 · HD · contact PI
DNA virus as vectors for cardiovascular diseases$9,870
P01 · FY2010 · HL · contact PI
DNA virus as vectors for cardiovascular diseases$1,854,749
P01 · FY2009 · HL · contact PI
Molecular therapy for CF and genetic diseases$1,186,890
P30 · FY2009 · DK · contact PI
Gene Therapy for Urea Cycle Disorders$980,295
P01 · FY2009 · HD · contact PI
NHLBI GTRP Preclinical Vector Production Core Laboratory$924,969
N01 · FY2009 · HL · contact PI
Regulated Transgene Expression in the Retina$494,560
RC1 · FY2009 · EY · contact PI
T Cell responses in Liver Gene therapy$408,632
P01 · FY2009 · HL · contact PI
Administrative Core$309,679
P30 · FY2009 · DK · contact PI
Molecular therapy for CF and genetic diseases$159,584
P30 · FY2009 · DK · contact PI
Administrative Core$140,043
P01 · FY2009 · HD · contact PI
Preclinical Studies of AAV Gene Therapy in MOuse Models of Urea Cycle Disorders$140,042
P01 · FY2009 · HD · contact PI
Immune Barriers to AAV Gene Therapy$140,042
P01 · FY2009 · HD · contact PI
Molecular therapy for CF and genetic diseases$119,899
P30 · FY2009 · DK · contact PI
Administrative Core$116,096
P01 · FY2009 · HL · contact PI
DNA virus as vectors for cardiovascular diseases$28,350
P01 · FY2009 · HL · contact PI
DNA virus as vectors for cardiovascular diseases$1,929,679
P01 · FY2008 · HL · contact PI
Gene Therapy for Urea Cycle Disorders$985,546
P01 · FY2008 · HD · contact PI
MOLECULAR THERAPY FOR CF AND GENETIC DISEASES$578,454
P30 · FY2008 · DK · contact PI
BIOLOGY OF AAV VECTORS$436,670
P01 · FY2008 · HL · contact PI
Immune Barriers to AAV Gene Therapy$122,894
P01 · FY2008 · HD · contact PI
Gene Therapy for Urea Cycle Disorders$122,883
P01 · FY2008 · HD · contact PI
Administrative Core$122,883
P01 · FY2008 · HD · contact PI
Preclinical Studies of AAV Gene Therapy in MOuse Models of Urea Cycle Disorders$122,883
P01 · FY2008 · HD · contact PI
DNA virus as vectors for cardiovascular diseases$1,918,557
P01 · FY2007 · HL · contact PI
MOLECULAR THERAPY FOR CYSTIC FIBROSIS (CF) AND GENETIC DISEASES$991,636
P30 · FY2007 · DK · contact PI
BIOLOGY OF AAV VECTORS$434,757
P01 · FY2007 · HL · contact PI
Vector Core$405,824
P30 · FY2007 · DK · contact PI
Animal$260,718
P30 · FY2007 · DK · contact PI
Immunology Core$144,506
P30 · FY2007 · DK · contact PI
Administrative Core$125,841
P30 · FY2007 · DK · contact PI
Pilot$54,747
P30 · FY2007 · DK · contact PI
DNA virus as vectors for cardiovascular diseases$1,925,010
P01 · FY2006 · HL · contact PI
MOLECULAR THERAPY FOR CF AND GENETIC DISEASES$871,527
P30 · FY2006 · DK · contact PI
BIOLOGY OF AAV VECTORS$421,366
P01 · FY2006 · HL · contact PI
Satellite Symposium to the ASGT Annual Meeting$10,000
R13 · FY2006 · DK · contact PI
DNA virus as vectors for cardiovascular diseases$1,920,797
P01 · FY2005 · HL
MOLECULAR THERAPY FOR CF AND GENETIC DISEASES$1,045,832
P30 · FY2005 · DK
BIOLOGY OF AAV VECTORS$411,208
P01 · FY2005 · HL
Xenograft Model of Cystic Fibrosis Therapy$356,625
R01 · FY2005 · HL
DNA virus as vectors for cardiovascular diseases$1,868,203
P01 · FY2004 · HL
MOLECULAR THERAPY FOR CF AND GENETIC DISEASES$1,049,748
P30 · FY2004 · DK
BIOLOGY OF AAV VECTORS$400,263
P01 · FY2004 · HL
Xenograft Model of Cystic Fibrosis Therapy$356,625
R01 · FY2004 · HL
DNA VIRUS AS VECTORS FOR CARDIOVASCULAR DISEASES$1,395,686
P01 · FY2003 · HL
MOLECULAR THERAPY FOR CF AND GENETIC DISEASES$1,056,542
P30 · FY2003 · DK
Xenograft Model of Cystic Fibrosis Therapy$356,625
R01 · FY2003 · HL
Pilot--Feasibility Program$126,800
P30 · FY2003 · DK
DNA VIRUS AS VECTORS FOR CARDIOVASCULAR DISEASES$1,358,676
P01 · FY2002 · HL
GENE THERAPY FOR CYSTIC FIBROSIS AND OTHER GENETIC DISEA$1,151,000
P30 · FY2002 · DK
Xenograft Model of Cystic Fibrosis Therapy$356,625
R01 · FY2002 · HL
CORE--VECTOR FACILITY$228,564
P30 · FY2002 · CA
BIOLOGY OF AAV AND FULLY DELETED ADENOVIRUS VECTORS$126,320
P01 · FY2002 · HL
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$124,146
M01 · FY2002 · RR
HIV-1 Vaccines based on Chimp serotypes of adenovirus$0
P01 · FY2002 · AI
Core--Vector Core$0
P01 · FY2002 · AI
DNA VIRUS AS VECTORS FOR CARDIOVASCULAR DISEASES$1,322,532
P01 · FY2001 · HL
GENE THERAPY FOR CYSTIC FIBROSIS AND OTHER GENETIC DISEA$1,151,000
P30 · FY2001 · DK
CORE--VECTOR FACILITY$276,701
P30 · FY2001 · CA
CORE--VECTOR FACILITY$228,564
P30 · FY2001 · CA
GENE THERAPY TRAINING--CYSTIC FIBROSIS/GENETIC DISEASES$144,305
T32 · FY2001 · DK
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$124,146
M01 · FY2001 · RR
BIOLOGY OF AAV AND FULLY DELETED ADENOVIRUS VECTORS$0
P01 · FY2001 · HL
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$0
M01 · FY2001 · RR
DNA VIRUS AS VECTORS FOR CARDIOVASCULAR DISEASES$1,287,442
P01 · FY2000 · HL
GENE THERAPY FOR CYSTIC FIBROSIS AND OTHER GENETIC DISEA$1,151,000
P30 · FY2000 · DK
XENOGRAFT MODEL OF CYSTIC FIBROSIS THERAPY$317,536
R01 · FY2000 · HL
CORE--VECTOR FACILITY$276,701
P30 · FY2000 · CA
BIOLOGY OF AAV AND FULLY DELETED ADENOVIRUS VECTORS$250,769
P01 · FY2000 · HL
GENE THERAPY TRAINING--CYSTIC FIBROSIS/GENETIC DISEASES$161,418
T32 · FY2000 · DK
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$25,114
M01 · FY2000 · RR
VECTORS FOR GENE THERAPY OF DUCHENNES MUSCULAR DYSTROPHY$0
P01 · FY2000 · AR
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$0
M01 · FY2000 · RR
EX VIVO GENE THERAPY OF FAMILIAL HYPERCHOLESTEROLEMIA$0
M01 · FY2000 · RR